ChemoCentryx (NASDAQ: CCXI)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-08 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.490 | -0.440 | 0.0500 | ||||
REV | 13.070M | 11.763M | -1.307M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of ChemoCentryx (NASDAQ: CCXI) through any online brokerage.
Other companies in ChemoCentryx’s space includes: Twist Bioscience (NASDAQ:TWST), Ultragenyx Pharmaceutical (NASDAQ:RARE), Cerevel Therapeutics Hldg (NASDAQ:CERE), Sage Therapeutics (NASDAQ:SAGE) and Fate Therapeutics (NASDAQ:FATE).
The latest price target for ChemoCentryx (NASDAQ: CCXI) was reported by Stifel on Wednesday, August 10, 2022. The analyst firm set a price target for 52.00 expecting CCXI to rise to within 12 months (a possible 2.24% upside). 12 analyst firms have reported ratings in the last year.
The stock price for ChemoCentryx (NASDAQ: CCXI) is $50.86 last updated August 16, 2022, 8:00 PM UTC.
There are no upcoming dividends for ChemoCentryx.
ChemoCentryx’s Q3 earnings are confirmed for Tuesday, November 8, 2022.
There is no upcoming split for ChemoCentryx.
ChemoCentryx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.